Connect with us

Hi, what are you looking for?

Brilliant AchievementBrilliant Achievement

Tech News

23andMe is ending its cancer research program and slashing over 200 jobs

An image showing the 23andMe sign
Photo by Justin Sullivan/Getty Images

23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s massive data breach and reverse its plummeting stock price. The genetic testing company also announced that it will shut down its therapeutics business.

Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a result, while “substantially” lowering operating expenses. 23andMe’s therapeutics division, which studied potential cancer treatments using its database of genetic material, will end all clinical trials, as the company considers licensing agreements or asset sales to “maximize” the program’s value.

23andMe has had a turbulent past year, with the…

Continue reading…

Join The Exclusive Subscription Today And Get Premium Articles For Free
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

You May Also Like

Editor's Pick

Thomas A. Berry and Alexander Khoury Since the creation of the market square, there have been boisterous, loquacious individuals who have solicited bids for...

Editor's Pick

We had a sneak preview of emerging leadership on the morning of July 12th. That was the morning the June Core CPI came in...

Editor's Pick

Colleen Hroncich A few years ago, EdChoice released what’s casually known as the Chicken Little report. The official title was a little less catchy...

Editor's Pick

Travis Fisher and Josh Loucks Just north of Boston in Everett, Massachusetts sits the poster child for irrational energy permitting in the United States....